Advertisement

Regulation of Prostaglandin Biosynthesis in Cultured Renal Medullary Interstitial Cells

  • Randall Mark Zusman

Abstract

Advances in the understanding of arachidonic acid metabolism have led to the isolation and identification of the prostaglandins (PGs), thromboxanes, prostacyclin, and leukotrienes. It is now known that virtually every cell of mammalian organisms is capable of initiating the metabolism of arachidonic acid, which was originally thought to be a unique product of the seminal vesicle. In every cell type the initiation of the synthetic cascade involves the release of arachidonic acid from its cellular storage pool, predominantly phospholipids and triglycerides, and conversion to the prostaglandin endoperoxides PGG2 and PGH2 by the cyclooxygenase enzyme. The subsequent synthesis of prostaglandins E2 and F, thromboxane A2, or prostacyclin (PGI2) is dependent upon the presence or absence of the specific enzymes responsible for the conversion of PGG2 and PGH2 to the respective end products. Thus an understanding of the regulation of prostaglandin biosynthesis at the cellular level is dependent upon the study of the rate-limiting step in the biosynthetic cascade. This rate-limiting reaction is the release of arachidonic acid from the cellular storage pool. Once liberated from the complex lipids within the cellular matrix and cell wall, the free arachidonate enters the cytoplasm and is rapidly metabolized. An understanding of the factors which affect the rate of arachidonic acid release from the phospholipid—triglyceride storage pool must therefore be the focus of an analysis of the cellular regulation of prostaglandin biosynthesis.

Keywords

Arachidonic Acid Angiotensin Converting Enzyme Inhibitor Phospholipase Activity Arachidonic Acid Release PGE2 Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bojesen IN: Fatty acid composition and depot function of lipid droplet triacylglycerols in renomedullary interstitial cells, in Mandai AK; Bohman SO (eds): The Renal Papilla and Hypertension. New York, Plenum Medical Book Company, 1980, pp 121–149.CrossRefGoogle Scholar
  2. 2.
    Muirhead EE, Germain G, Leach BE, et al: Production of renomedullary prostaglandins by renomedullary interstitial cells in tissue culture. Circ Res 30–31 (Suppl II): 161–170, 1972.Google Scholar
  3. 3.
    Zusman RM, Keiser HR: Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture: Stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Clin Invest 60: 215–223, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Zusman RM, Keiser HR: Prostaglandin E2 biosynthesis by rabbit renomedullary intrestitial cells in tissue culture: Mechanism of stimulation by angiotensin II, bradykinin, and anginine vasopressin. J Biol Chem 252: 2069–2071, 1977.PubMedGoogle Scholar
  5. 5.
    Zusman RM, Brown CA: Role of phospholipase in the regulation of prostaglandin E2 biosynthesis by rabbit renomedullary interstitial cells in tissue: Effects of angiotensin II, potassium, hyperosmolality, dexamethasone and protein synthesis inhibition. Adv Prost Thromb Res 6: 243–248, 1980.Google Scholar
  6. 6.
    Bell RL, Kennerly DA, Sanford N, et al: Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc Nat Acad Sci USA 76: 3238–3241, 1979.CrossRefGoogle Scholar
  7. 7.
    Brown CA, Zusman RM, Haber E: Identification of an angiotensin receptor in rabbit renomedullary interstitial cells in tissue culture: Correlation with prostaglandin biosynthesis. Circ Res 46: 802–807, 1980.PubMedGoogle Scholar
  8. 8.
    Beck TR, Hassid, Dunn MJ: The effect of arginine vasopressin and its analogues on the synthesis of PGE2 by rat renal medullary interstitial cells in culture. Pharmacol Exp Ther 215: 15–19, 1980.Google Scholar
  9. 9.
    Dunn MJ, Kinter LB, Beeuwkes R, et al: Interaction of vasopressin and renal prostaglandins in the homozygous diabetes insipidus rat. Adv Prost Thromb Res 7: 1009–1016, 1980.Google Scholar
  10. 10.
    Zusman RM, Keiser HR, Handler JS: Vasopressin-stimulated prostaglandin E biosynthesis in the toad urinary bladder: Effect on water flow. J Clin Invest 60: 1339–1347, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Smith WL, Bell TG: Immunohistochemical localization of the prostaglandin forming cyclooxygenase in renal cortex. Am J Physiol 235: F451–456, 1978.PubMedGoogle Scholar
  12. 12.
    Zusman RM, Keiser HR: Regulation of prostaglandin E2 synthesis by angiotensin II, potassium, osmotality and dexamethasone. Kidney Int 17: 277–283, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Gill JR: Banter’s Syndrome. Annu Rev Med 31: 405–419, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Flower RJ, Blackwell GJ: Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278: 456–459, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Hirata F, Schiffman E, Venkatasubramanian K, et al: A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Nat Acad Sci USA 77: 2533–2536, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Hirata F, Axelrod J: Biochemical mechanism of signal transduction across biomembranes. Submitted for publication.Google Scholar
  17. 17.
    Wong PYK, Cheung WY: Calmodulin stimulated human platelet phospholipase A2. Biochem Biophys Res Commun 90: 473–480, 1979.PubMedCrossRefGoogle Scholar
  18. 18.
    Haber E: The renin—angiotensin system and hypertension. Kidney Int 15: 427–444, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Cushman DW, Cheung HS, Sabo EF, et al: Angiotensin converting enzyme inhibitors: Evolution of a new class of antihypertensive drugs, in Horowitz ZP (ed): Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications, Baltimore, Urban and Schwarzenberg, 1981, pp 3–26.Google Scholar
  20. 20.
    Marks ES, Bing RF, Thurston H, et al: Vasopressor property of the converting enzyme inhibitor captopril (SQ 14225): The role of factors other than renin-angiotensin blockade in the rat. Clin Sci 58: 1–6, 1980.PubMedGoogle Scholar
  21. 21.
    Muirhead EE, Brooks B, Brosius WL: Antihypertensive action of captopril in angiotensin-salt hypertension. Arch Pathol Lab Med 104: 631–634, 1980.PubMedGoogle Scholar
  22. 22.
    Swartz EL, Williams GH, Hollenberg NK, et al: Endocrine profile in the longterm phase of converting enzyme inhibition. Clin Pharmacol Ther 28: 499–508, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ14225 in man. N Engl J Med 298: 991–995, 1978.PubMedCrossRefGoogle Scholar
  24. 24.
    Swartz SL, Williams GH, Hollenberg NK, et al: Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 65: 1257–1264, 1980.PubMedCrossRefGoogle Scholar
  25. 25.
    Vinci JM, Horwitz D, Zusman RM, et al: The effect of converting enzyme inhibition with SQ 20881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1: 416–426, 1979.Google Scholar
  26. 26.
    Swartz SL, Williams GH, Hollenberg NK, et al: Converting enzyme inhibition in essential hypertension: The hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1: 106–111, 1979.PubMedGoogle Scholar
  27. 27.
    Goldstone RM, Martin K, Zipser R, et al: Evidence for a dual action of converting enzyme inhibitor on blood pressure in normal man. Prostaglandins 22: 587–598, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Dzau. VJ, Colucci WS, Williams GH, et al: Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 302: 1373–1379, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Galler M, Folkert VW, Schlondorff D. Effect of converting enzyme inhibitor of prostaglandin synthesis by isolated rat glomeruli. Clin Res 29: 271A, 1981.Google Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • Randall Mark Zusman
    • 1
    • 2
  1. 1.Medical Services, Cardiac and Hypertension UnitsMassachusetts General HospitalBostonUSA
  2. 2.Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations